# **2022 Grand Plenary Speakers**

## Monday June 27 7:30 am – 12:00 noon

Featuring the following special guest lecturers!

## **CSNR Terbrugge Lecture**

### **The Brain Stress Test**



Dr. David Mikulis, MD, FRCP(C)

is a staff Neuroradiologist, Full Professor at the University of Toronto, and Senior Scientist at the Toronto Western Hospital Research Institute. He is past president of two societies including the Eastern Neuroradiological Society and the American Society of Functional Neuroradiology (ASFNR). He was

recently recognized in 2019 as an inaugural founding fellow of the ASFNR. In 1993, Dr. Mikulis established one of the first fMRI labs in Canada and has continued as the Director of this functional neuroimaging research lab in the Joint Department of Medical Imaging at the University Health network. In that role he has supported over 250 researchers, mentored over 50 university degree candidates, and authored 300 peer reviewed papers. He is currently involved in developing translational neurovascular imaging methods with two major program arms. The first is cerebrovascular blood vessel wall imaging, and the second is quantitative measurement and clinical application of cerebrovascular reactivity (CVR) for assessing deficiencies in brain blood flow regulation. Both of these programs have led to successful translation into the clinic.

# **CSCN Gloor Lecture**

# Cannabinoids for the Treatment of Neurological Disorders



### Daniel Friedman, MD, MSc is a

Professor (Clinical) of Neurology at NYU Grossman School of Medicine and a member of the Comprehensive Epilepsy Center. He is also the co-director of the Video-EEG laboratory at NYU Langone Medical Center. He received his medical degree from Case Western Reserve University School of Medicine, completed his neurology residency training at the

Hospital of the University of Pennsylvania and his epilepsy/clinical neurophysiology fellowship at the Neurological Institute/Columbia University Medical Center. He specializes in the treatment of teenagers and adults with difficult to control epilepsy. He also performs research to better understand the causes of morbidity and mortality of epilepsy and test interventions to improve outcomes. He also serves on the executive committees of the North American SUDEP Registry and the Epilepsy Study Consortium and on the professional advisory board of the Epilepsy Foundation of America and the EF/SUDEP Institute.

## **CACN Tibbles Lecture**

## **EEG Monitoring in Critically III Children**



**Dr. Nicholas Abend** is an Associate Professor of Neurology, Pediatrics, and Anesthesia and Critical Care at the University of Pennsylvania and the Children's Hospital of Philadelphia. He is the Medical Director of Clinical Neurophysiology, the Director of Neurology Strategy and Inpatient Operations, and an Associate Scholar in the Center for Epidemiology and

Biostatistics. His clinical practice focuses on seizure management and EEG interpretation in critically ill children and intractable epilepsy management. His research focuses on the significance, pathophysiology, and appropriate management of electrographic seizures in critically ill children and neonates, the treatment of status epilepticus, and the utility of EEG as a prognostic biomarker in children and neonates with acute encephalopathy. He has served as Chair Critical Care EEG Monitoring Research Consortium and a member of the American Clinical Neurophysiology Society's Council, and he is a Fellow of the American Epilepsy Society and American Clinical Neurophysiology Society.



Browse the 2022 CNSF Congress program and event details at <u>eventscribe.net/2022/cnsfcongress</u> or click the QR code.

## **CNSS Penfield Lecture**

## Immunotherapy in Neuro-Oncology



#### John H. Sampson, MD, PhD,

MHSc, MBA, is the Robert H. and Gloria Wilkins Distinguished Professor and Chair of Neurosurgery at Duke University School of Medicine, and co-leader of the Duke Cancer Institute Neuro-Oncology program.

Dr. Sampson is a recognized leader in the surgical resection and experimental treatment of complex brain tumors.

He currently focuses his clinical practice on treating patients with benign and malignant brain tumors and divides his time between his clinical practice and an active research laboratory investigating new modalities of direct brain tumor infusion and immunotherapy.

After earning his medical degree from the University of Manitoba in Winnipeg, Dr. Sampson went on to pursue his PhD in neuropathology and MHSc in clinical research at Duke University. He did his research training under the internationally renowned scientist, Darell D. Bigner, and Nobel Laureate Gertrude Elion. Recognizing the need for additional health sector management and leadership training, he completed an MBA with Duke University's Fuqua School of Business.

He has authored more than 240 peer-reviewed publications documenting the development of multiple immunotherapeutic agents that have affected the standard of care in glioblastoma multiforme, the most malignant form of brain cancer. He has remained continuously funded by the National Institutes of Health since 2000. Dr. Sampson is a member of the prestigious National Academy of Medicine as well as the Association of American Physicians. In 2018, he was named president of the Private Diagnostic Clinic (PDC), the physician practice of Duke Health with over 1,600 members.

## **CSC Sandra Black Lecture**

Proteinopathy meets Small Vessel Disease: how biomarker advancement will help unravel complex inter-relationships in aging, dementia and stroke'



#### Sandra E Black, O.C., O.Ont., Hon.DSc., MD, FRCP(C), FRSC, FANA,

FAHA, FAAN is a Professor of Medicine (Neurology) at Sunnybrook Health Sciences Centre, University of Toronto. An internationally known cognitive and stroke neurologist, she has been actively engaged in clinical trials for >30 years. She was inaugural Executive Director of the Toronto Dementia Research Alliance

(2012-20), a collaborative of U of T's academic memory programs, which assess 2000 new patients a year. In April 2020, she became Scientific Director of the Dr. Sandra Black Centre for Brain Resilience and Recovery, through a \$10M anonymous lead gift. She has published >650 peer publications (+70 invited) (Google HI 120; >70,00 citations) in a 30-year research career bridging dementia and stroke, using standardized neuroimaging, cognitive, functional and neuropsychiatric measures, genetics, and neuropathology to study brain-behavior relationships in the common dementias, with a focus on inter- relationships of Small Vessel Disease and neurodegenerative disorders. Recognitions include Fellowship, Royal Society of Canada, UofT's Faculty of Medicine Dean's Alumni Lifetime Achievement Award, an Honorary Doctor of Science from the University of Waterloo, the Distinguished Achievement Award of AAN's Society of Cognitive and Behavioural Neurology, and UBC's 2022 Margolese Brain Disorders prize, recognizing Canadians who have made outstanding contributions to amelioration and treatment of brain disorders. She was appointed Member of the Order of Ontario (2011) and Officer in the Order of Canada in 2015 for her contributions to Alzheimer's disease, stroke and vascular dementia.

# Don't miss these Grand Plenary Speakers Download the CNSF Congress App

Access the most up-to-date information about the Congress; including schedules, session highlights, notifications, maps and much more. Log in or create an account to favorite a presentation, access your personal schedule, take notes or send feedback. Registered attendees have the added benefit of course material and evaluation surveys to claim CME credits.



Search for **CNSF Congress** in the App Store on your iPhone, iPad, or Android device. Download it for **free** and start planning your experience.

Mobile App sponsored by Paladin Labs.



CNSF